Picard Medical's Losses Double Amid Soaring Interest, Derivative Costs

TL;DR

**PMI is bleeding cash and needs more money, making it a high-risk bet for traders.**

AI Summary

Picard Medical, Inc. (PMI) reported a significant increase in net loss for the six months ended June 30, 2025, reaching $12.285 million, a substantial rise from $6.011 million in the same period of 2024. This was primarily driven by a sharp increase in interest expense to $2.982 million from $254,000, and a derivative loss of $2.505 million compared to $61,000 in the prior year. Product revenues saw a modest increase to $2.744 million from $2.617 million, while total cost of revenues also rose to $3.229 million from $2.249 million, resulting in a gross loss of $485,000. Operating expenses increased slightly to $6.282 million from $6.121 million. The company's cash and cash equivalents improved to $410,000 as of June 30, 2025, from $96,000 at December 31, 2024, largely due to $5.112 million in financing activities, including $2.000 million from convertible notes and $1.485 million from common stock issuance. PMI continues to face a going concern risk due to ongoing operating losses and negative cash flows, necessitating further debt or equity financing.

Why It Matters

For investors, PMI's escalating net losses and significant going concern warning signal high risk, indicating a potential need for further dilutive equity raises or restrictive debt. Employees face uncertainty given the company's reliance on external financing to sustain operations. Customers of the SynCardia TAH, a critical medical device, could be impacted by any operational disruptions if financing efforts fail. In the broader medical device market, PMI's struggles highlight the capital-intensive nature of developing and commercializing advanced medical technologies, especially for smaller players competing with larger, more established firms.

Risk Assessment

Risk Level: high — The company explicitly states it has incurred operating losses and negative cash flows for the six months ended June 30, 2025, and expects these to continue, raising "substantial doubt about its ability to continue as a going concern." Total liabilities surged to $45.931 million as of June 30, 2025, from $35.842 million at December 31, 2024, driven by a significant increase in derivative liability to $13.711 million and loans from related parties to $6.810 million.

Analyst Insight

Investors should exercise extreme caution and consider avoiding PMI stock given the explicit going concern warning and rapidly increasing losses. Those already invested should re-evaluate their position, considering the high likelihood of further dilution from future equity raises or the potential for bankruptcy if financing cannot be secured on favorable terms.

Financial Highlights

debt To Equity

N/A

revenue

$2.744M

operating Margin

N/A

total Assets

$11.703M

total Debt

$45.931M

net Income

-$12.285M

eps

N/A

gross Margin

-17.7%

cash Position

$410K

revenue Growth

+4.8%

Revenue Breakdown

Key Numbers

• $12.285M — Net Loss (Increased from $6.011M in prior year, a 104% increase)
• $2.982M — Interest Expense (Increased from $254K in prior year, a 1074% increase)
• $2.505M — Derivative Loss (Increased from $61K in prior year, a 4006% increase)
• $45.931M — Total Liabilities (Increased from $35.842M at Dec 31, 2024, a 28% increase)
• $410K — Cash and Cash Equivalents (Increased from $96K at Dec 31, 2024, but remains low for operations)
• $4.782M — Net Cash Used in Operating Activities (For six months ended June 30, 2025, indicating ongoing cash burn)
• 73,701,176 — Common Shares Outstanding (As of September 11, 2025, indicating potential for further dilution)
• $2.744M — Product Revenues (Modest increase from $2.617M in prior year, a 4.8% increase)
• $6.810M — Loans from Related Parties (Increased from $5.148M at Dec 31, 2024, showing reliance on related party financing)
• $13.711M — Derivative Liability (Increased from $6.759M at Dec 31, 2024, a 103% increase)

Key Players & Entities

• Picard Medical, Inc. (company) — registrant
• SynCardia Systems, LLC (company) — acquired subsidiary
• SynCardia GmbH (company) — operating subsidiary
• SEC (regulator) — Securities and Exchange Commission
• NYSE American LLC (company) — exchange where common stock is registered
• $12.285 million (dollar_amount) — net loss for six months ended June 30, 2025
• $6.011 million (dollar_amount) — net loss for six months ended June 30, 2024
• $2.982 million (dollar_amount) — interest expense for six months ended June 30, 2025
• $2.505 million (dollar_amount) — derivative loss for six months ended June 30, 2025
• $45.931 million (dollar_amount) — total liabilities as of June 30, 2025

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company has experienced significant operating losses, with a net loss of $12.285 million for the six months ended June 30, 2025, compared to $6.011 million in the prior year. This, coupled with negative cash flows from operations ($4.782 million used for the six months ended June 30, 2025), raises substantial doubt about its ability to continue as a going concern. The company's ability to meet its obligations is dependent on securing additional financing.
• Increasing Debt Load [high — financial]: Total liabilities increased by 28% to $45.931 million as of June 30, 2025, from $35.842 million at December 31, 2024. This increase is partly driven by a rise in loans from related parties to $6.810 million and a significant increase in derivative liability to $13.711 million.
• High Interest Expense and Derivative Losses [high — financial]: Interest expense surged to $2.982 million for the six months ended June 30, 2025, from $254,000 in the prior year. Additionally, the company incurred a derivative loss of $2.505 million, a substantial increase from $61,000, significantly contributing to the widened net loss.
• Negative Gross Profit [medium — operational]: The company reported a gross loss of $485,000 for the six months ended June 30, 2025, as total cost of revenues ($3.229 million) exceeded product revenues ($2.744 million). This indicates challenges in managing the cost of goods sold relative to sales generated.
• Low Cash Position [high — financial]: Despite an increase to $410,000 in cash and cash equivalents as of June 30, 2025, from $96,000 at December 31, 2024, the cash balance remains critically low for ongoing operations, especially given the substantial net losses and cash burn.
• Reliance on Related Party Financing [medium — financial]: Loans from related parties increased to $6.810 million as of June 30, 2025, from $5.148 million at December 31, 2024. This highlights a continued dependence on financing from entities connected to the company, which may have implications for terms and availability.
• Potential for Shareholder Dilution [medium — financial]: With 73,701,176 common shares outstanding as of September 11, 2025, and the company's need for further financing, there is a significant risk of future equity issuances that could dilute existing shareholders' ownership.
• Derivative Liability Volatility [high — market]: The derivative liability has more than doubled to $13.711 million as of June 30, 2025, from $6.759 million at December 31, 2024. This volatility, coupled with significant derivative losses recognized in the income statement, suggests exposure to market risks that could impact financial performance.

Industry Context

The medical device industry is highly competitive and capital-intensive, requiring significant R&D investment and facing stringent regulatory hurdles. Companies like Picard Medical often rely on external financing to fund innovation and market entry. The current environment may see increased pressure on pricing and reimbursement, alongside evolving technological advancements.

Regulatory Implications

As a medical device company, PMI is subject to rigorous regulatory oversight by bodies like the FDA. Compliance with manufacturing standards, clinical trial requirements, and post-market surveillance is critical. Any failure to meet these standards can result in product recalls, fines, and significant reputational damage, impacting financial stability.

What Investors Should Do

1. Monitor future financing rounds closely.
2. Scrutinize cost management and revenue generation strategies.
3. Evaluate the impact of derivative instruments and debt obligations.
4. Assess the company's ability to secure additional funding.

Key Dates

• 2025-06-30: Six Months Ended — Reporting period showing a significant increase in net loss, driven by higher interest and derivative expenses, alongside a gross loss.
• 2025-06-30: Balance Sheet Date — Indicates increased total liabilities ($45.931M) and a low cash position ($410K), highlighting ongoing financial challenges.
• 2024-12-31: Previous Year End Balance Sheet Date — Provides a baseline for comparison, showing a substantial increase in liabilities and a lower cash position compared to the current period.
• 2024-06-30: Prior Year Six Months Ended — Used for year-over-year comparison, highlighting the dramatic increase in net loss, interest expense, and derivative losses.

Glossary

Derivative Liability

A financial instrument whose value is derived from an underlying asset, index, or rate. A liability indicates that the company owes value related to this instrument. (The significant increase in derivative liability ($13.711M) and associated losses ($2.505M) are major contributors to the company's widening net loss and financial instability.)

Going Concern

An accounting assumption that a business will continue to operate for the foreseeable future. If there is substantial doubt, it must be disclosed. (The company's ongoing operating losses and negative cash flows raise substantial doubt about its ability to continue as a going concern, necessitating disclosure and potential for further financing.)

Accumulated Deficit

The total cumulative net losses of a company since its inception, less any net income. It represents a negative balance in retained earnings. (The accumulated deficit has grown to ($62.126 million) as of June 30, 2025, reflecting the company's history of unprofitability.)

Convertible Notes Payable

Debt instruments that can be converted into a predetermined amount of equity (stock) of the issuing company. (These notes represent a significant portion of current liabilities ($14.752M) and carry the potential for future equity dilution upon conversion.)

Gross Profit (Loss)

Revenue minus the cost of goods sold. A negative number indicates a loss on the direct costs of producing goods or services. (Picard Medical reported a gross loss of $485,000 for the six months ended June 30, 2025, indicating that the cost of revenues exceeded product revenues.)

Right-of-use Assets

Assets recognized under lease accounting standards, representing the right to use an underlying asset for the lease term. (These assets, related to operating and finance leases, contribute to the company's overall asset base and liabilities, though their impact on the current financial distress is secondary.)

Year-Over-Year Comparison

Compared to the prior year's six-month period, Picard Medical, Inc. has seen a dramatic deterioration in its financial performance. Net loss has more than doubled to $12.285 million from $6.011 million, primarily due to a massive surge in interest expense (up 1074% to $2.982 million) and derivative losses (up 4006% to $2.505 million). While product revenues saw a modest 4.8% increase to $2.744 million, the cost of revenues also rose significantly, resulting in a gross loss. Total liabilities have also increased substantially by 28% to $45.931 million, while the cash position remains precariously low at $410,000, underscoring the company's heightened financial risks.

Key Financial Figures

• $0.0001 — ch Registered Common stock, par value $0.0001 per share PMI NYSE American LLC I

Filing Documents

• picardmedical_10q.htm (10-Q) — 1133KB
• picardmedical_ex31-1.htm (EX-31.1) — 19KB
• picardmedical_ex31-2.htm (EX-31.2) — 19KB
• picardmedical_ex32-1.htm (EX-32.1) — 8KB
• picardmedical_ex32-2.htm (EX-32.2) — 8KB
• 0001829126-25-007334.txt ( ) — 6385KB
• pmi-20250630.xsd (EX-101.SCH) — 52KB
• pmi-20250630_cal.xml (EX-101.CAL) — 55KB
• pmi-20250630_def.xml (EX-101.DEF) — 183KB
• pmi-20250630_lab.xml (EX-101.LAB) — 401KB
• pmi-20250630_pre.xml (EX-101.PRE) — 344KB
• picardmedical_10q_htm.xml (XML) — 1058KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements 1 Unaudited Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024 1 Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and six months ended June 30, 2025 and 2024 2 Unaudited Condensed Consolidated Statements of Changes in Temporary Equity and Stockholders' Deficit for the three and six months ended June 31, 2025 and 2024 3 Unaudited Condensed Consolidated Statements of Cash Flows for the six months ended June 31, 2025 and 2024 4

Notes to Financial Statements (Unaudited)

Notes to Financial Statements (Unaudited) 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 30 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 38 Item 4.

Controls and Procedures

Controls and Procedures 38

OTHER INFORMATION

PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 40 Item 1A.

Risk Factors

Risk Factors 40 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds from Registered Securities 40 Item 3. Defaults Upon Senior Securities 40 Item 4. Mine Safety Disclosures 40 Item 5. Other Information 40 Item 6. Exhibits 41 i CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (the "Form 10-Q") includes statements that are, or may be deemed to be, "forward-looking statements" within the meaning of the U.S. federal securities laws, are statements of future expectations and other forward-looking statements.

Forward-looking statements can be identified by the use of forward-looking terminology such as "aim,"

Forward-looking statements can be identified by the use of forward-looking terminology such as "aim," "anticipate," "believe," "continue," "could," "estimate," "expect," "forecast," "future," "guidance," "intend," "may," "opportunity," "plan," "potential," "predict," "projected," "should," "strategy," "suggests," "targets," "will," "will be" or "would" or similar expressions or the negatives thereof, or other variations thereof, or comparable terminology, or by discussions of strategy, plans or intentions. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this Form 10-Q and include statements regarding the intentions, beliefs or current expectations of our management teams concerning, among other things, their respective results of operations, financial condition, liquidity, prospects, growth, strategies, and the industry in which they operate. You are cautioned that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from those made in or suggested by the forward-looking statements contained in this Form 10-Q. In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this Form 10-Q, those results or developments may not be indicative of results or developments in subsequent periods. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance and our actual financial condition, results of operations and cash flows. The development of the industry in which we oper

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION ITEM 1.

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS. PICARD MEDICAL, INC. UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share amounts) June 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 410 $ 96 Accounts receivable 1,300 513 Inventory, net 6,996 8,115 Due from related parties 112 112 Prepaid expenses and other current assets 825 955 Total current assets 9,643 9,791 Property and equipment, net 188 227 Finance lease right-of-use assets, net 154 177 Operating lease right-of-use assets, net 550 700 Intangible assets, net 553 596 Goodwill 615 615 Total assets $ 11,703 $ 12,106 Liabilities, Temporary Equity, and Stockholders' Deficit Current liabilities: Accounts payable $ 6,370 $ 5,293 Current portion of finance lease liability 63 63 Current portion of operating lease liability 366 371 Loans from related parties 6,810 5,148 Convertible notes payable, net 14,752 14,828 Derivative liability 13,711 6,759 Accrued interest 1,371 761 Other accrued liabilities 2,193 2,102 Total current liabilities 45,636 35,325 Finance lease liability, net of current portion 61 96 Operating lease liability, net of current portion 234 421 Total liabilities 45,931 35,842 Commitments and contingencies (Note 7) Temporary equity: Preferred stock, $ 0.0001 par value; 30,000,000 shares authorized; 18,406,857 Series A-1 issued and outstanding as of June 30, 2025 and December 31, 2024; liquidation value $ 26,981 and $ 25,405 as of June 30, 2025 and December 31, 2024, respectively 20,265 20,265 Stockholders' deficit: Common stock, $ 0.0001 par value; 150,000,000 shares authorized; 10,334,363 and 9,286,235 shares issued as of June 30, 2025 and December 31, 2024, respectively of which 8,991,713 and 7,943,585 are outstanding as of June 30, 2025 and December 31, 2024, respectively 1 1 Ad

View Full Filing

View this 10-Q filing on SEC EDGAR